Entering text into the input field will update the search result below

Amarin stock rises after Q4 earnings beat amid Vascepa generic competition

Mar. 01, 2022 7:42 AM ETAmarin Corporation plc (AMRN) StockBy: Ravikash, SA News Editor6 Comments

Trading Charts on a Display

da-kuk/E+ via Getty Images

Amarin (NASDAQ:AMRN) rose pre-market after its Q4 results beat analysts' estimates.

Full year 2021 total net revenue decreased 5.03% Y/Y to $583.19M. Net product revenue fell 4% Y/Y to $580.32M.

The company said the decrease was

Recommended For You

Comments (6)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

sts66 profile picture
"This net loss included $45.8 million in non-cash stock-based compensation expense."

How about canceling those RSU's the execs and BOD no longer deserve?
Hawaiian Investa profile picture
Great earnings, loading loading loading
This still is the best CV drug available from the MACE data perspective. My hope would be a acquisition from large Pharma with an additional international foot print. This drug is standard of care per all guidelines. Still buying.
Cora Schlesinger profile picture
Acquisition ASAP. O/w pps is going to languish.
fire0nice228 profile picture
a long way from $20
Wow!! $0.4 move

About AMRN

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Amarin Corporation plc
Avid Bioservices, Inc.
Kamada Ltd.
TScan Therapeutics, Inc.
Voyager Therapeutics, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.